Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBIT Margin (2021 - 2025)

Historic EBIT Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 256.36%.

  • InMed Pharmaceuticals' EBIT Margin fell 536000.0% to 256.36% in Q4 2025 from the same period last year, while for Dec 2025 it was 174.87%, marking a year-over-year decrease of 120500.0%. This contributed to the annual value of 160.77% for FY2025, which is 175000.0% up from last year.
  • As of Q4 2025, InMed Pharmaceuticals' EBIT Margin stood at 256.36%, which was down 536000.0% from 162.54% recorded in Q3 2025.
  • InMed Pharmaceuticals' EBIT Margin's 5-year high stood at 20.99% during Q2 2023, with a 5-year trough of 1626.64% in Q4 2021.
  • Its 5-year average for EBIT Margin is 450.84%, with a median of 202.75% in 2024.
  • As far as peak fluctuations go, InMed Pharmaceuticals' EBIT Margin skyrocketed by 12456200bps in 2023, and later crashed by -1375500bps in 2024.
  • InMed Pharmaceuticals' EBIT Margin (Quarter) stood at 1626.64% in 2021, then skyrocketed by 71bps to 471.26% in 2022, then skyrocketed by 72bps to 132.64% in 2023, then plummeted by -53bps to 202.75% in 2024, then dropped by -26bps to 256.36% in 2025.
  • Its last three reported values are 256.36% in Q4 2025, 162.54% for Q3 2025, and 139.49% during Q2 2025.